Compare Moody's Corporation (MCO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs ResMed Inc. — how do they compare? Moody's Corporation trades at $490.77 (market cap $88.28B), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: Moody's Corporation is far larger — about 3.1× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| MCO | RMD | |
|---|---|---|
Market Cap | $88.28B | $28.81B |
Sector | Financials | Health |
52-Week High | $539.61 | $293.73 |
52-Week Low | $412.23 | $182.82 |
Enterprise Value | $94.08B | $27.99B |
Dividend Yield | 0.82% | 1.21% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
